Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-Month BDLL Regimen vs Standard Long-Course for RR-TB in Hubei
NCT07198685Not yet recruiting
- Sponsor
- Wuhan Pulmonary Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of delamanid in Tuberculosis (TB) (2 arms), sponsored by Wuhan Pulmonary Hospital. Primary endpoint: End of treatment outcome at 72 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
delamanid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07198685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198685.